XERS · Insider Trading
Xeris Biopharma Holdings, Inc. Common Stock
Every open-market purchase and sale reported by XERS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Beth Hecht | See Remarks | Sell | −16,666 | −$156.79K |
| 2026-10-02 | Kevin McCulloch | See Remarks | Sell | −15,000 | −$141.12K |
| 2026-10-02 | Steven Pieper | See Remarks | Sell | −5,000 | −$47.04K |
| 2026-09-29 | Kevin McCulloch | See Remarks | Sell | −25,000 | −$250.00K |
| 2026-09-01 | Kevin McCulloch | See Remarks | Sell | −15,000 | −$127.31K |
| 2026-09-01 | Steven Pieper | See Remarks | Sell | −5,000 | −$42.50K |
| 2026-09-01 | Beth Hecht | See Remarks | Sell | −16,666 | −$141.43K |
| 2026-08-21 | John Patrick Shannon Jr | See Remarks | F | −36,645 | −$296.09K |
| 2026-08-21 | Kevin McCulloch | See Remarks | F | −21,918 | −$177.10K |
| 2026-08-12 | Steven Pieper | See Remarks | Sell | −5,000 | −$42.50K |
| 2026-08-04 | Kevin McCulloch | See Remarks | Sell | −15,000 | −$120.24K |
| 2026-08-04 | Beth Hecht | See Remarks | Sell | −16,666 | −$133.55K |
| 2026-07-07 | Steven Pieper | See Remarks | Sell | −45,000 | −$383.18K |
| 2026-07-02 | Kevin McCulloch | See Remarks | Sell | −90,000 | −$722.51K |
| 2026-07-02 | Nerissa Kreher | Director | A | +33,582 | — |
| 2026-07-02 | Beth Hecht | See Remarks | Sell | −16,666 | −$133.86K |
| 2026-06-05 | John Johnson | Director | MIXED | +9,193 | −$91.42K |
| 2026-06-05 | James Aloysius Brady | Director | A | +24,193 | — |
| 2026-06-05 | Barbara-Jean Anne Bormann-Kennedy | Director | MIXED | +8,193 | −$97.51K |
| 2026-06-05 | Marla Persky | Director | MIXED | +8,693 | −$91.43K |
| 2026-06-05 | Garheng Kong | Director | A | +24,193 | — |
| 2026-06-05 | Dawn Halkuff | Director | MIXED | +4,193 | −$121.89K |
| 2026-06-02 | Beth Hecht | See Remarks | Sell | −16,667 | −$100.98K |
| 2026-05-01 | Beth Hecht | See Remarks | Sell | −16,667 | −$103.81K |
| 2026-04-03 | Beth Hecht | See Remarks | Sell | −16,667 | −$99.86K |
| 2026-04-01 | James Aloysius Brady | Director | Sell | −10,834 | −$60.04K |
| 2026-03-16 | Kevin McCulloch | See Remarks | M | +48,898 | +$199.99K |
| 2026-03-05 | Steven Pieper | See Remarks | M | +41,927 | +$197.31K |
| 2026-03-04 | Beth Hecht | See Remarks | Sell | −16,667 | −$104.09K |
| 2026-02-25 | Anh Tu Nguyen | See Remarks | F | −29,300 | −$201.58K |
| 2026-02-02 | Anh Tu Nguyen | See Remarks | A | +121,293 | — |
| 2026-02-02 | Kevin McCulloch | See Remarks | MIXED | +42,401 | −$927.82K |
| 2026-02-02 | Steven Pieper | See Remarks | MIXED | −50,548 | −$1.51M |
| 2026-02-02 | John Patrick Shannon Jr | See Remarks | MIXED | +137,931 | −$2.51M |
| 2026-02-02 | Beth Hecht | See Remarks | MIXED | −64,929 | −$1.37M |
| 2026-01-09 | Kevin McCulloch | See Remarks | Sell | −15,000 | −$120.00K |
| 2026-01-06 | John Patrick Shannon Jr | See Remarks | MIXED | +67,394 | −$26.26K |
| 2026-01-05 | Beth Hecht | See Remarks | Sell | −16,667 | −$123.78K |
| 2025-12-19 | John Johnson | Director | Sell | −135,400 | −$977.02K |
| 2025-12-15 | Barbara-Jean Anne Bormann-Kennedy | Director | Sell | −15,000 | −$106.41K |
| 2025-12-02 | Beth Hecht | See Remarks | Sell | −16,667 | −$116.78K |
| 2025-11-17 | John Patrick Shannon Jr | See Remarks | MIXED | +72,828 | −$24.49K |
| 2025-11-13 | Beth Hecht | See Remarks | Sell | −16,667 | −$123.30K |
| 2025-10-03 | Kevin McCulloch | See Remarks | F | −733 | −$6.09K |
| 2025-09-15 | Kevin McCulloch | See Remarks | J | −2,000 | — |
| 2025-09-12 | Marla Persky | Director | Sell | −15,500 | −$119.61K |
| 2025-08-29 | Jeffrey W Sherman | Director | MIXED | +4,808 | −$21.23K |
| 2025-08-15 | John Johnson | Director | Sell | −107,500 | −$786.46K |
| 2025-08-13 | Dawn Halkuff | Director | Sell | −42,500 | −$309.23K |
| 2025-08-04 | Kevin McCulloch | See Remarks | F | −14,651 | −$78.82K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John Patrick Shannon Jr | See Remarks | 2,898,933 | $29.89M |
| Kevin McCulloch | See Remarks | 1,624,208 | $16.75M |
| Steven Pieper | See Remarks | 1,351,053 | $13.93M |
| Beth Hecht | See Remarks | 1,111,130 | $11.46M |
| John Johnson | Director | 683,083 | $7.04M |
| Anh Tu Nguyen | See Remarks | 398,733 | $4.11M |
| Kenneth Erland Johnson | See Remarks | 346,288 | $3.57M |
| Jeffrey W Sherman | Director | 266,820 | $2.75M |
| Garheng Kong | Director | 238,337 | $2.46M |
| Marla Persky | Director | 157,063 | $1.62M |
| Barbara-Jean Anne Bormann-Kennedy | Director | 150,693 | $1.55M |
| Dawn Halkuff | Director | 124,603 | $1.28M |
| James Aloysius Brady | Director | 113,359 | $1.17M |
| Nerissa Kreher | Director | 33,582 | $346.23K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XERS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.